Poverty and prevalence of antimicrobial resistance in invasive isolates

International Journal of Infectious Diseases

Volumn 52, Issue , 2016, Pages 59-61

  Alvarez Uria, Gerardo ^a   Gandra, Sumanth ^b   Laxminarayan, Ramanan ^b,c,d,e  

^a Rural Development Trust Hospital   (India)

^b Center for Disease Dynamics Economics and Policy   (India)

^c PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^d PRINCETON UNIVERSITY   (United States)

^e Centre for Disease Dynamics Economics and Policy   (United States)

Author keywords

Antibiotic; Antimicrobial resistance; Low and middle income countries; Poverty; Sanitation

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; METICILLIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; COMMUNITY; DEPENDENT VARIABLE; EPIDEMIOLOGY; ESCHERICHIA COLI; GROSS NATIONAL INCOME; HIGH INCOME COUNTRY; HOSPITAL; KLEBSIELLA; LINEAR REGRESSION ANALYSIS; LOW INCOME COUNTRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE INCOME COUNTRY; NONHUMAN; NONLINEAR REGRESSION ANALYSIS; POVERTY; PREVALENCE; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HUMANS; KLEBSIELLA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; POVERTY; PREVALENCE;

EID: 84992195988     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.09.026     Document Type: Article

References (9)

1. 1 Holmes, A.H., Moore, L.S., Sundsfjord, A., Steinbakk, M., Regmi, S., Karkey, A., et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 387 (2016), 176–187, 10.1016/S0140-6736(15)00473-0.
2. 2 World Health Organization, Antimicrobial resistance: global report on surveillance. 2014, WHO, Geneva, Switzerland.
3. 3 Gelband, H., Miller-Petrie, M., Pant, S., Gandra, S., Levinson, J., Barter, D., et al. The state of the world's antibiotics, 2015. 2015, Center for Disease Dynamics, Economics & Policy (CDDEP), Washington, DC.
4. 4 ResistanceMap. Center for Disease Dynamics, Economics & Policy (CDDEP). Available at: http://resistancemap.cddep.org/.(accessed July 11, 2016).
5. 5 World Health Organization, World Health Statistics 2011. 2011, WHO, Geneva.
6. 6 de Kraker, M.E., Davey, P.G., Grundmann, H., on behalf of the BURDEN Study Group. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med, 8, 2011, e1001104, 10.1371/journal.pmed.1001104#pmed.1001104.s004.
7. 7 Alvarez-Uria, G., Priyadarshini, U., Naik, P.K., Midde, M., Reddy, R., Mortality associated with community-acquired cephalosporin-resistant Escherichia coli in patients admitted to a district hospital in a resource-limited setting. Clin Pract, 2, 2012, e76, 10.4081/cp.2012.e76.
8. 8 Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.A., Klugman, K., et al. Access to effective antimicrobials: a worldwide challenge. Lancet 387 (2016), 168–175, 10.1016/S0140-6736(15)00474-2.
9. 9 Van Boeckel, T.P., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B.T., Levin, S.A., et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 14 (2014), 742–750, 10.1016/S1473-3099(14)70780-7.